MedTrace Logo

Psychopharmacotherapy for Depressive Patients

NCT06054321 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2024-04-18

No results posted yet for this study

Summary

The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.

Conditions

Interventions

DRUG

stepwise pharmacotherapy

In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

DRUG

antidepressant monotherapy group

In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

Sponsors & Collaborators

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Jae-Min Kim, MD, PhD · Chonnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2028-12-31
Completion
2030-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054321 on ClinicalTrials.gov